Zkusit zdarma
Nuvation Bio Inc.

Nuvation Bio Inc.

NUVB
Cena:
$ 4.72
-0.07 (-1.46%)
Valuace
70
Růst
70
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Nuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript

Nuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript

21:00 22-05-2026

Nuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Trans...

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer

16:05 13-05-2026

Thermo Fisher Scientific, the world leader in serving science, will now manufacture drug product for...

Nuvation Bio Inc. (NUVB) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Nuvation Bio Inc. (NUVB) Presents at Bank of America Global Healthcare Conference 2026 Transcript

12:40 13-05-2026

Nuvation Bio Inc. (NUVB) Presents at Bank of America Global Healthcare Conference 2026 Transcript...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)

10:56 07-05-2026

NEW YORK, May 7, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Nuv...

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer

8:00 06-05-2026

Application includes updated TRUST-I TKI-naïve median duration of response (mDOR) and median progre...

Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio to Participate in Upcoming Investor Conferences

16:05 05-05-2026

NEW YORK, May 5, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focu...

Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call Transcript

Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call Transcript

21:33 04-05-2026

Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call Transcript...

Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates

Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates

18:50 04-05-2026

Nuvation Bio Inc. (NUVB) came out with quarterly earnings of $0.01 per share, missing the Zacks Cons...

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

16:10 04-05-2026

Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI ® (taletrectinib);...

Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth

Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth

11:05 27-04-2026

Nuvation Bio (NUVB) doesn't possess the right combination of the two key ingredients for a likely ea...

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

8:00 27-04-2026

Guidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-...

Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

18:00 21-04-2026

Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median d...

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

16:05 20-04-2026

NEW YORK, April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company f...

Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)

Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)

0:04 13-04-2026

200,000 Class A shares were sold for a transaction value of `$904,000 at around $4.52 per share on A...

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

10:26 07-04-2026

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is ...

Capricorn Fund Managers Ltd Makes New Investment in Nuvation Bio Inc. $NUVB

Capricorn Fund Managers Ltd Makes New Investment in Nuvation Bio Inc. $NUVB

4:43 06-04-2026

Capricorn Fund Managers Ltd bought a new position in shares of Nuvation Bio Inc. (NYSE: NUVB) in the...

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

13:19 02-04-2026

NEW YORK, April 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves...

Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo

Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo

8:00 01-04-2026

With acquisition of Japan rights, Nuvation Bio now has global development and commercialization righ...

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

16:05 26-03-2026

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered g...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

10:00 26-03-2026

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor...

close

NUVATION BIO ANNOUNCES PIVOTAL GLOBAL PHASE 3 SIGMA TRIAL (G203) FOR SAFUSIDENIB IN IDH1-MUTANT GLIOMA

09-02-2026
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES 2026 OUTLOOK AHEAD OF 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

12-01-2026
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO AND EISAI ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR TALETRECTINIB IN EUROPE AND ADDITIONAL COUNTRIES OUTSIDE U.S., CHINA AND JAPAN

12-01-2026
NEW YORK & TOKYO--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB, CORPORATE HEADQUARTERS: NEW YORK, ...
Více zde

NUVATION BIO TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

06-01-2026
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

INNOVENT ANNOUNCES INCLUSION OF SEVEN INNOVATIVE DRUGS INCLUDING TYVYT NEW INDICATION AND SYCUME IN CHINA'S NATIONAL REIMBURSEMENT DRUG LIST

06-12-2025
SAN FRANCISCO AND SUZHOU, CHINA, DEC. 6, 2025 /PRNEWSWIRE/ -- INNOVENT BIOLOGICS, INC. ("INNOVENT"...
Více zde

NUVATION BIO ANNOUNCES PUBLICATION OF POSITIVE PHASE 2 STUDY RESULTS FOR SAFUSIDENIB FOR THE TREATMENT OF GRADE 2 IDH1-MUTANT GLIOMA IN NEURO-ONCOLOGY

03-12-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

26-11-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

03-11-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO ENROLLS FIRST PATIENT IN GLOBAL, RANDOMIZED STUDY OF SAFUSIDENIB FOR MAINTENANCE TREATMENT OF HIGH-GRADE IDH1-MUTANT GLIOMA

23-10-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON NOVEMBER 3, 2025

20-10-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO ENROLLS FIRST PATIENT IN TRUST-IV PHASE 3 STUDY OF IBTROZI™ (TALETRECTINIB) FOR THE ADJUVANT TREATMENT OF ROS1-POSITIVE EARLY-STAGE NON-SMALL CELL LUNG CANCER

30-09-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO RECEIVES APPROVAL FROM JAPAN'S MINISTRY OF HEALTH, LABOUR AND WELFARE FOR IBTROZITM FOR PATIENTS WITH ADVANCED ROS1-POSITIVE NON-SMALL CELL LUNG CANCER

19-09-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO ANNOUNCES NEW DATA FROM PIVOTAL CLINICAL STUDIES OF IBTROZI™ (TALETRECTINIB) IN ADVANCED ROS1-POSITIVE NON-SMALL CELL LUNG CANCER AT 2025 WORLD CONFERENCE ON LUNG CANCER

07-09-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

27-08-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

07-08-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY TACKLING SOME O...
Více zde

NUVATION BIO TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON AUGUST 7, 2025

24-07-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO ANNOUNCES NATIONAL COMPREHENSIVE CANCER NETWORK® ADDS TALETRECTINIB (IBTROZI™) AS PREFERRED OPTION TO CLINICAL PRACTICE GUIDELINES IN ONCOLOGY FOR ADVANCED ROS1+ NON-SMALL CELL LUNG CANCERS

24-06-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

ONCO360 HAS BEEN SELECTED AS A NATIONAL SPECIALTY PHARMACY PARTNER FOR IBTROZI™ (TALETRECTINIB), MANUFACTURED BY NUVATION BIO INC.

16-06-2025
LOUISVILLE, KY., JUNE 16, 2025 (GLOBE NEWSWIRE) -- ONCO360®, THE NATION'S LEADING INDEPENDENT SPECI...
Více zde

U.S. FOOD AND DRUG ADMINISTRATION APPROVES NUVATION BIO'S IBTROZI™ (TALETRECTINIB), A NEXT-GENERATION ORAL TREATMENT FOR ADVANCED ROS1-POSITIVE NON-SMALL CELL LUNG CANCER

11-06-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO TO PRESENT NEW DATA FROM PIVOTAL CLINICAL STUDIES OF TALETRECTINIB IN ADVANCED ROS1-POSITIVE NON-SMALL CELL LUNG CANCER AT ASCO 2025 ANNUAL MEETING

21-05-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO TO PRESENT MATCHING-ADJUSTED INDIRECT COMPARISON DATA FOR TALETRECTINIB VS. ENTRECTINIB AT ISPOR 2025

13-05-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON TACK...
Více zde

NUVATION BIO TO PRESENT AT THE CITIZENS LIFE SCIENCES CONFERENCE

01-05-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY TACKLING SOME O...
Více zde

NUVATION BIO TO REPORT RESULTS FOR FIRST QUARTER 2025 AND PROVIDE BUSINESS UPDATE ON MAY 7, 2025

22-04-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL ONCOLOGY COMPANY FOCUSED ON SOLV...
Více zde

NUVATION BIO TO PRESENT AT THE JONES HEALTHCARE AND TECHNOLOGY INNOVATION CONFERENCE

02-04-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL BIOPHARMACEUTICAL COMPANY TACKLI...
Více zde

NUVATION BIO TO PRESENT NEW NONCLINICAL DATA FOR TALETRECTINIB AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2025

25-03-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL BIOPHARMACEUTICAL COMPANY TACKLI...
Více zde

NUVATION BIO TO PRESENT MATCHING-ADJUSTED INDIRECT COMPARISON DATA FOR TALETRECTINIB VS. CRIZOTINIB DURING MINI ORAL PRESENTATION AT THE EUROPEAN LUNG CANCER CONGRESS 2025

25-03-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL BIOPHARMACEUTICAL COMPANY TACKLI...
Více zde

NUVATION BIO REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

06-03-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL BIOPHARMACEUTICAL COMPANY TACKLI...
Více zde

NUVATION BIO SECURES UP TO $250 MILLION IN NON-DILUTIVE FINANCINGS FROM SAGARD HEALTHCARE PARTNERS

03-03-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL BIOPHARMACEUTICAL COMPANY TACKLI...
Více zde

NUVATION BIO TO PRESENT AT THE TD COWEN 45TH ANNUAL HEALTH CARE CONFERENCE

24-02-2025
NEW YORK--(BUSINESS WIRE)--NUVATION BIO INC. (NYSE: NUVB), A GLOBAL BIOPHARMACEUTICAL COMPANY TACKLI...
Více zde

KUEHN LAW ENCOURAGES INVESTORS OF NUVATION BIO INC. TO CONTACT LAW FIRM

18-02-2025
NEW YORK , FEB. 18, 2025 /PRNEWSWIRE/ -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVE...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-12 00:00:008-KStáhnout
2025-11-26 00:00:008-KStáhnout
2025-11-17 00:00:008-KStáhnout
2025-11-03 00:00:008-KStáhnout
2025-11-03 00:00:0010-QStáhnout
2025-08-07 01:00:008-KStáhnout
2025-08-07 01:00:0010-QStáhnout
2025-08-07 00:00:008-KStáhnout
2025-08-07 00:00:0010-QStáhnout
2025-06-11 01:00:008-KStáhnout
2025-06-11 00:00:008-KStáhnout
2025-05-23 01:00:008-KStáhnout
2025-05-23 00:00:008-KStáhnout
2025-05-07 01:00:008-KStáhnout
2025-05-07 01:00:0010-QStáhnout
2025-05-07 00:00:008-KStáhnout
2025-05-07 00:00:0010-QStáhnout
2025-03-25 00:00:008-KStáhnout
2025-03-24 23:00:008-KStáhnout
2025-03-06 00:00:008-KStáhnout
2025-03-06 00:00:0010-KStáhnout
2025-03-05 23:00:008-KStáhnout
2025-03-05 23:00:0010-KStáhnout
2025-03-05 00:00:008-KStáhnout
2025-03-04 23:00:008-KStáhnout
2025-03-04 00:00:008-KStáhnout
2025-03-03 23:00:008-KStáhnout
2025-02-12 00:00:008-KStáhnout
2025-02-11 23:00:008-KStáhnout
2024-11-06 00:00:008-KStáhnout
2024-11-06 00:00:0010-QStáhnout
2024-11-05 23:00:008-KStáhnout
2024-11-05 23:00:0010-QStáhnout
2024-09-05 01:00:008-KStáhnout
2024-09-05 00:00:008-KStáhnout
2024-08-05 01:00:008-KStáhnout
2024-08-05 01:00:0010-QStáhnout
2024-08-05 00:00:008-KStáhnout
2024-08-05 00:00:0010-QStáhnout
2024-05-14 01:00:008-KStáhnout
2024-05-14 01:00:0010-QStáhnout
2024-05-14 00:00:008-KStáhnout
2024-05-14 00:00:0010-QStáhnout
2024-04-10 01:00:008-KStáhnout
2024-04-10 00:00:008-KStáhnout
2024-03-25 00:00:008-KStáhnout
2024-03-24 23:00:008-KStáhnout
2024-02-29 00:00:008-KStáhnout
2024-02-29 00:00:0010-KStáhnout
2024-02-28 23:00:008-KStáhnout
2024-02-28 23:00:0010-KStáhnout
2024-01-08 00:00:008-KStáhnout
2024-01-07 23:00:008-KStáhnout
2023-12-14 00:00:008-KStáhnout
2023-12-13 23:00:008-KStáhnout
2023-11-27 00:00:008-KStáhnout
2023-11-26 23:00:008-KStáhnout
2023-11-13 00:00:008-KStáhnout
2023-11-12 23:00:008-KStáhnout
2023-11-02 00:00:008-KStáhnout
2023-11-02 00:00:0010-QStáhnout
2023-11-01 23:00:008-KStáhnout
2023-11-01 23:00:0010-QStáhnout
2023-08-03 01:00:008-KStáhnout
2023-08-03 01:00:0010-QStáhnout
2023-08-03 00:00:008-KStáhnout
2023-08-03 00:00:0010-QStáhnout
2023-05-16 01:00:008-KStáhnout
2023-05-16 00:00:008-KStáhnout
2023-05-04 01:00:008-KStáhnout
2023-05-04 01:00:0010-QStáhnout
2023-05-04 00:00:008-KStáhnout
2023-05-04 00:00:0010-QStáhnout
2023-03-15 00:00:008-KStáhnout
2023-03-15 00:00:0010-KStáhnout
2023-03-14 23:00:008-KStáhnout
2023-03-14 23:00:0010-KStáhnout
2023-03-02 00:00:008-KStáhnout
2023-03-01 23:00:008-KStáhnout
2022-12-23 00:00:008-KStáhnout
2022-12-22 23:00:008-KStáhnout
2022-11-03 00:00:008-KStáhnout
2022-11-03 00:00:0010-QStáhnout
2022-11-02 23:00:008-KStáhnout
2022-11-02 23:00:0010-QStáhnout
2022-08-04 01:00:008-KStáhnout
2022-08-04 01:00:0010-QStáhnout
2022-08-04 00:00:008-KStáhnout
2022-08-04 00:00:0010-QStáhnout
2022-08-01 01:00:008-KStáhnout
2022-08-01 00:00:008-KStáhnout
2022-05-17 01:00:008-KStáhnout
2022-05-17 00:00:008-KStáhnout
2022-05-09 01:00:008-KStáhnout
2022-05-09 01:00:0010-QStáhnout
2022-05-09 00:00:008-KStáhnout
2022-05-09 00:00:0010-QStáhnout
2022-02-28 00:00:008-KStáhnout
2022-02-28 00:00:0010-KStáhnout
2022-02-27 23:00:008-KStáhnout
2022-02-27 23:00:0010-KStáhnout
2022-01-10 00:00:008-KStáhnout
2022-01-09 23:00:008-KStáhnout
2021-11-10 00:00:008-KStáhnout
2021-11-10 00:00:0010-QStáhnout
2021-11-09 23:00:008-KStáhnout
2021-11-09 23:00:0010-QStáhnout
2021-10-28 01:00:008-KStáhnout
2021-10-28 00:00:008-KStáhnout
2021-08-12 01:00:008-KStáhnout
2021-08-12 01:00:0010-QStáhnout
2021-08-12 00:00:008-KStáhnout
2021-08-12 00:00:0010-QStáhnout
2021-06-04 01:00:008-KStáhnout
2021-06-04 00:00:008-KStáhnout
2021-05-17 01:00:008-KStáhnout
2021-05-17 01:00:0010-QStáhnout
2021-05-17 00:00:008-KStáhnout
2021-05-17 00:00:0010-QStáhnout
2021-05-14 01:00:008-KStáhnout
2021-05-14 00:00:008-KStáhnout
2021-03-11 00:00:008-KStáhnout
2021-03-11 00:00:0010-KStáhnout
2021-03-10 23:00:008-KStáhnout
2021-03-10 23:00:0010-KStáhnout
2021-02-12 00:00:008-KStáhnout
2021-02-11 23:00:008-KStáhnout
2021-02-09 00:00:008-KStáhnout
2021-02-08 23:00:008-KStáhnout
2020-11-16 00:00:0010-QStáhnout
2020-11-15 23:00:0010-QStáhnout
2020-10-21 01:00:008-KStáhnout
2020-10-21 00:00:008-KStáhnout
2020-08-20 01:00:008-KStáhnout
2020-08-20 00:00:008-KStáhnout
2020-08-14 01:00:0010-QStáhnout
2020-08-14 00:00:0010-QStáhnout
2020-07-10 01:00:008-KStáhnout
2020-07-10 00:00:008-KStáhnout
2020-07-06 01:00:008-KStáhnout
2020-07-06 00:00:008-KStáhnout
preloader